Moslem Maryam, Mahmoudabadi Ali Zarei
Infectious and Tropical Diseases Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Department of Medical Mycology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Iran J Microbiol. 2020 Apr;12(2):170-176.
Luliconazole is currently confirmed for the topical therapy of dermatophytosis. Moreover, it is found that luliconazole has activity against some molds and yeast species. The aim of the present study was to evaluate the efficacy of luliconazole in comparison to routine used antifungals on clinical and environmental isolates of .
Thirty eight isolates of (18 environmental and 20 clinical isolates) were detected based on morphological and microscopic features and also PCR-sequencing of β-tubulin ribosomal DNA gene. All the isolates were tested against luliconazole, voriconazole, amphotericin B and caspofungin. Minimum inhibitory concentration (MIC), MIC, MIC and MIC Geometric (GM) were calculated using CLSI M38-A2 protocol for both environmental and clinical isolates.
Luliconazole with extremely low MIC range, 0.00049-0.00781 μg/mL and MIC 0.00288 μg/mL showed very strong activity against both clinical and environmental isolates. Moreover, voriconazole inhibited 100% of isolates at defined epidemiological cutoff values (ECV ≤ 2 μg/ml). 50% and 27.8% of clinical and environmental isolates of , were resistant to caspofungin, respectively. Whereas, all the isolates were found to be resistant to amphotericin B.
The analysis of our data clearly indicated that luliconazole (with MIC 0.00244 μg/ml for clinical and 0.00336 μg/ml for environmental isolates) had the highest activity against strains.
卢立康唑目前已被确认为用于皮肤癣菌病的局部治疗。此外，还发现卢立康唑对某些霉菌和酵母菌具有活性。本研究的目的是评估卢立康唑与常规使用的抗真菌药物相比，对临床和环境分离株的疗效。
基于形态学和显微镜特征以及β-微管蛋白核糖体DNA基因的PCR测序，检测了38株（18株环境分离株和20株临床分离株）。所有分离株均针对卢立康唑、伏立康唑、两性霉素B和卡泊芬净进行测试。使用CLSI M38 - A2方案计算环境和临床分离株的最低抑菌浓度（MIC）、MIC、MIC和MIC几何均值（GM）。
卢立康唑的MIC范围极低，为0.00049 - 0.00781μg/mL，MIC为0.00288μg/mL，对临床和环境分离株均显示出很强的活性。此外，伏立康唑在规定的流行病学截断值（ECV≤2μg/ml）下抑制了100%的分离株。50%和27.8%的临床和环境分离株对卡泊芬净耐药。而所有分离株均对两性霉素B耐药。
对我们数据的分析清楚地表明，卢立康唑（临床分离株的MIC为0.00244μg/ml，环境分离株的MIC为0.00336μg/ml）对菌株具有最高的活性。
